Medical Information

Saphnelo is a biological agent used for the treatment of systemic lupus erythematosus (SLE), administered via intravenous infusion. The standard dose is 300mg, administered every 4 weeks, and should be handled by professional medical personnel. Common side effects include upper respiratory tract infections, headaches, etc. Serious adverse reactions require close monitoring. The following provides a detailed explanation from three aspects: indications, usage, dosage, and side effects.

Indications for Saphnelo monoclonal antibody

Annilumab is suitable for adult patients with moderate to severe systemic lupus erythematosus, especially those who have poor response to standard treatment. This drug inhibits type I interferon receptors, regulates immune abnormalities, and improves disease activity.

2. Usage and dosage of Saphnelo monoclonal antibody

(1) Administration method: intravenous infusion, lasting about 30 minutes each time.

(2) Standard dose: 300mg/time, once every 4 weeks.

(3) Dose adjustment: During severe infection, medication should be suspended and evaluated for continued treatment after recovery.

3. Side effects of Saphnelo monoclonal antibody

(1) Common reactions: upper respiratory tract infection (25%), headache (15%), nausea (10%), etc.

(2) Serious risks: opportunistic infections, allergic reactions, worsening of depressive symptoms, with an incidence rate of less than 5%.

(3) Monitoring requirements: Screening for tuberculosis before medication, regular assessment of infection signs and mental health during treatment.

4 Precautions about Saphnelo monoclonal antibody

(1) Taboo: Prohibited for individuals with active infections or allergies to ingredients.

(2) Special population: Safety data during pregnancy is limited, and it is necessary to weigh the pros and cons during lactation.

(3) Interaction: Co administration with live vaccines may reduce vaccine efficacy, it is recommended to have a 4-week interval.